Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An acquired form of hemophilia A, resulting in spontaneous bleeding in individuals with no history of bleeding disorders. It is believed to be caused by spontaneous inhibition of clotting factor VIII by autoantibodies, and is usually associated with other autoimmune conditions.
Biomarker and diagnostic research for acquired hemophilia A has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
5 clinical trials registered, 3 recruiting. Interventions under study include drug therapy. Pipeline includes 1 PHASE4, 1 PHASE2, 1 NA. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05345197](https://clinicaltrials.gov/study/NCT05345197) |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 11:21 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about acquired hemophilia A
Emicizumab in Patients With Acquired Hemophilia A
PHASE2 |
University of Washington |
ACTIVE_NOT_RECRUITING |
[NCT05849740](https://clinicaltrials.gov/study/NCT05849740) | An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A | PHASE4 | Institute of Hematology & Blood Diseases Hospital, China | RECRUITING |
[NCT06550882](https://clinicaltrials.gov/study/NCT06550882) | A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea | — | Takeda | RECRUITING |
[NCT06461533](https://clinicaltrials.gov/study/NCT06461533) | A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A | — | Takeda | RECRUITING |
[NCT07789587](https://clinicaltrials.gov/study/NCT07789587) | A Study of Bometase Alfa for Bleeding Control in Acquired Hemophilia A | NA | Institute of Hematology & Blood Diseases Hospital, China | NOT_YET_RECRUITING |
149 publications have been identified in PubMed for acquired hemophilia A. Kisho has analyzed 59 by research type. Research spans Review / Meta-Analysis (37%), Case Report / Case Series (25%), and Clinical Trial Publication (8%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 22 | 37% |
Patient case studies | 15 | 25% |
Clinical study results | 5 | 8% |
Disease patterns and progression | 5 | 8% |
Other research | 4 | 7% |
Testing and diagnosis research | 3 | 5% |
New treatment approaches | 3 | 5% |
Laboratory research | 2 | 3% |
Iarossi M (2026). [PMID: 42097159](https://pubmed.ncbi.nlm.nih.gov/42097159/). *Hamostaseologie*. [Case Report / Case Series]
Mingot-Castellano ME (2026). [PMID: 40820842](https://pubmed.ncbi.nlm.nih.gov/40820842/). *Haematologica*. [Epidemiology / Natural History]
Cuschera F (2026). [PMID: 40273904](https://pubmed.ncbi.nlm.nih.gov/40273904/). *Acta Haematol*. [Case Report / Case Series]
Hebraud L (2026). [PMID: 41878977](https://pubmed.ncbi.nlm.nih.gov/41878977/). *Rev Prat*. [Review / Meta-Analysis]
Rossio R (2026). [PMID: 41560780](https://pubmed.ncbi.nlm.nih.gov/41560780/). *Res Pract Thromb Haemost*. [Basic Science / Preclinical]
Haider MZ (2026). [PMID: 32809329](https://pubmed.ncbi.nlm.nih.gov/32809329/). *Unknown Journal*. [Other]
Gurumurthy G (2026). [PMID: 40925410](https://pubmed.ncbi.nlm.nih.gov/40925410/). *Semin Thromb Hemost*. [Gene Therapy / Novel Therapeutics]
Carlson AL (2026). [PMID: 41110512](https://pubmed.ncbi.nlm.nih.gov/41110512/). *J Thromb Haemost*. [Review / Meta-Analysis]
Szappanos Á (2026). [PMID: 42158567](https://pubmed.ncbi.nlm.nih.gov/42158567/). *Pathol Oncol Res*. [Review / Meta-Analysis]
Turincev P (2025). [PMID: 41079435](https://pubmed.ncbi.nlm.nih.gov/41079435/). *Res Pract Thromb Haemost*. [Diagnostic / Biomarker]
AI-curated news mentioning acquired hemophilia A
Updated Sep 2, 2026
A multicenter real-life study provides new insights into acquired hemophilia, highlighting its prevalence and management in a middle-income country. The findings may inform future treatment strategies and improve patient outcomes.
A recent case report highlights the complexities of acquired hemophilia A, detailing instances of hematoma, hemarthrosis, and hemotympanum. This study contributes to the understanding of the clinical manifestations associated with this rare bleeding disorder.
A recent cost-effectiveness analysis evaluates the use of emicizumab in hospitalized older patients with acquired hemophilia A. The study provides insights into the economic implications of this treatment option for a vulnerable patient population.